Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures steady with focus on Mideast talks, US-China summit
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
Vanda Pharma (VNDA) Buy Rating and $15 PT Reiterated - Jefferies
May 5, 2016 9:45 AM EDTJefferies analyst, Chris Howerton, maintained his Buy rating and $15 PT after Vanda (NASDAQ: VNDA) reported a strong 1Q with 3 takeaways:
1) Hetlioz - strong 1Q sales (~$16.2M vs Jef est. of ~$15.4M) suggt'ng ~80 net patient adds in our model; EU launch in 3Q16 mgmt... More
Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 7c
May 4, 2016 5:31 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $32.57 million.
2016 Financial Guidance
Vanda reiterates its prior 2016 financial guidance and expects to achieve the following... More
